OV- The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by DRP – Poster published at ASCO
Hoersholm, Denmark, June 5th, 2017 – Oncology Venture Sweden AB (“Oncology Venture”) today announced that the previously published abstract with DRP data for epirubicin for breast cancer was presented as a poster on the poster session ‘Breast Cancer—Metastatic’ Board 63; Abstract 1071 on the 4th of June 2017 at 8:00 AM-11:30 AM local time/15:00-18:30 CET. The title is “Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort”. The DRP was significantly associated